BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 31829045)

  • 1. Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies.
    Santoni M; Conti A; Massari F; Di Nunno V; Faloppi L; Galizia E; Morbiducci J; Piva F; Buti S; Iacovelli R; Ferretti B; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Battelli N; Montironi R
    Expert Rev Cardiovasc Ther; 2019 Dec; 17(12):917-927. PubMed ID: 31829045
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
    Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
    Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis.
    Chacón MR; Enrico DH; Burton J; Waisberg FD; Videla VM
    JAMA Netw Open; 2018 Dec; 1(8):e185617. PubMed ID: 30646278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials.
    Berardi R; Santoni M; Rinaldi S; Nunzi E; Smerilli A; Caramanti M; Morgese F; Torniai M; Savini A; Fiordoliva I; Onofri A; Pistelli M; Taccaliti A; Cascinu S
    PLoS One; 2016; 11(5):e0152079. PubMed ID: 27167519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; Andrikou K; Bittoni A; Lanese A; Pistelli M; Pantano F; Vincenzi B; Armento G; Massari F; Tonini G; Cascinu S; Santini D
    Crit Rev Oncol Hematol; 2015 Nov; 96(2):206-19. PubMed ID: 26070625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
    Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
    Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
    Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis.
    Palazzo A; Ciccarese C; Iacovelli R; Cannizzaro MC; Stefani A; Salvatore L; Bria E; Tortora G
    ESMO Open; 2023 Apr; 8(2):101154. PubMed ID: 36893518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
    Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the addition of drugs targeting the vascular endothelial growth factor pathway to first-line chemotherapy increase complete response? A meta-analysis of randomized clinical trials.
    Li Y; Liang XY; Yue YQ; Sheng L; Liu JK; Wang ZY; Chen G
    Tumour Biol; 2016 May; 37(5):6297-306. PubMed ID: 26619847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
    Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
    Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2014 Oct; 10(12):1981-92. PubMed ID: 25386814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
    Qi WX; Tang LN; He AN; Yao Y; Shen Z
    Respir Med; 2013 Aug; 107(8):1280-3. PubMed ID: 23810268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: a systematic review and meta-analysis of randomized controlled trials.
    Funakoshi T; Latif A; Galsky MD
    Cancer Treat Rev; 2014 Jun; 40(5):636-47. PubMed ID: 24629273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.